Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.

Autor:	Abel EJ; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: abel@urology.wisc.edu., Masterson TA; Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana., Karam JA; Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas., Master VA; Department of Urology, Emory University School of Medicine, Atlanta, Georgia., Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas., Hutchinson R; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas., Lorentz CA; Department of Urology, Emory University School of Medicine, Atlanta, Georgia., Bloom E; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin., Bauman TM; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin., Wood CG; Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas., Blute ML Jr; Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Jazyk:	angličtina
Zdroj:	The Journal of urology [J Urol] 2017 Oct; Vol. 198 (4), pp. 810-816. Date of Electronic Publication: 2017 Apr 12.
DOI:	10.1016/j.juro.2017.04.066
Abstrakt:	Purpose: Following surgery for nonmetastatic renal cell carcinoma with tumor thrombus the risk of recurrence is significant but variable among patients. The purpose of this study was to develop and validate a predictive nomogram for individual estimation of recurrence risk following surgery for renal cell carcinoma with venous tumor thrombus. Materials and Methods: Comprehensive data were collected on patients with nonmetastatic renal cell carcinoma and thrombus treated at a total of 5 institutions from 2000 to 2013. Independent predictors of recurrent renal cell carcinoma from a competing risks analysis were developed into a nomogram. Predictive accuracy was compared between the development and validation cohorts, and between the nomogram and the UISS (UCLA Integrated Staging System, SSIGN (Stage, Size, Grade and Necrosis) and Sorbellini models. Results: A total of 636 patients were analyzed, including the development cohort of 465 and the validation cohort of 171. Independent predictors, including tumor diameter, body mass index, preoperative hemoglobin less than the lower limit of normal, thrombus level, perinephric fat invasion and nonclear cell histology, were developed into a nomogram. Estimated 5-year recurrence-free survival was 49% overall. Five-year recurrence-free survival in patients with 0, 1, 2 and more than 2 risk factors was 77%, 53%, 47% and 20%, respectively. Predictive accuracy was similar in the development and validation cohorts (AUC 0.726 and 0.724, respectively). Predictive accuracy of the thrombus nomogram was higher than that of the UISS (AUC 0.726 vs 0.595, p = 0.001), SSIGN (AUC 0.713 vs 0.612, p = 0.04) and Sorbellini models (AUC 0.709 vs 0.638, p = 0.02). Conclusions: We present a predictive nomogram for postoperative recurrence in patients with nonmetastatic renal cell carcinoma with venous thrombus. Improving individual postoperative risk assessment may allow for better design and analysis of future adjuvant clinical trials. (Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu